The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
Open accessAbstract
In previous in vitro studies, we have shown that murine splenocytes or cancer patient lymphocytes incubated in IL-2 become lytic for fresh syngeneic or autologous tumors. We have now performed the adoptive transfer of such lymphokine-activated killer (LAK) cells in a murine B16 metastasis model to test their in vivo efficacy. 1 X 10(8) LAK cells, infused intravenously into C57BL/6 mice with established B16 pulmonary metastases, led to a marked decreased in the number of lung nodules and improved survival. LAK cells administered 3 d after amputation of a tumor-bearing limb also decreased the incidence of spontaneous pulmonary metastases. LAK cells generated from tumor-bearer splenocytes had effects equivalent to those from normal animals, and this antimetastatic effect of the LAK cells did not require the prior administration of cyclophosphamide or other immunosuppressants. Fresh or unstimulated splenocytes had no effect. The antitumor effectors and precursors in vivo and in vitro were Thy-1+. The lymphokine required for the activation appeared to be interleukin 2 (IL-2), since incubation in partially purified supernatants from PMA pulsed EL-4 or Con A-pulsed splenocytes or purified Jurkat IL-2 led to the generation of LAK cells equally active in vivo. The use of IL-2-activated cells may provide a valuable method for the adoptive therapy of human neoplasms as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grimm, E. A., Mazumder, A., Zhang, H. Z., & Rosenberg, S. A. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.6.1823 · Cited by 2,204
Self-citationSelection of Successive Tumour Lines for Metastasis
FIDLER, I. J. (1973) · Nature New Biology · doi:10.1038/newbio242148a0 · Cited by 1,361
North, R. J. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.4.1063 · Cited by 650
Thymoma production of T cell growth factor (Interleukin 2).
Farrar, J. J., Fuller-Farrar, J., Simon, P. L., Hilfiker, M. L., Stadler, B. M., & Farrar, W. L. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.6.2555 · Cited by 481
Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo.
Hanna, N., & Burton, R. C. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.127.5.1754 · Cited by 394
Rollinghoff, M., Starzinski-Powitz, A., Pfizenmaier, K., & Wagner, H. (1977) · The Journal of Experimental Medicine · doi:10.1084/jem.145.2.455 · Cited by 335
Cheever, M. A., Greenberg, P. D., Fefer, A., & Gillis, S. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.4.968 · Cited by 265
Yron, I., Wood, T. A., Spiess, P. J., & Rosenberg, S. A. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.1.238 · Cited by 264
Self-citationPassive Immunotherapy of Cancer in Animals and Man
(1977) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60637-5 · Cited by 243
Karre, K., Seeley, J., Eriksson, E., Burton, R., & Kiessling, R. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.156.2.385 · Cited by 241
Cited by
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Self-citationRosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Self-citationRosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
Self-citationMulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Self-citationT cell receptor (TCR) signaling in health and disease
Shah, K., Al-Haidari, A., Sun, J., & Kazi, J. U. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00823-w · Cited by 604
Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli
Rosenberg, S. A., Grimm, E. A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K., & Mark, D. F. (1984) · Science · doi:10.1126/science.6367046 · Cited by 595
Self-citationKarnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
Rosenberg, S. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.180 · Cited by 390
Self-citationClinical effects and toxicity of interleukin-2 in patients with cancer
Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A., & Rosenberg, S. A. (1986) · Cancer · doi:10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z · Cited by 355
Self-citationImmune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Guillaume, T., Rubinstein, D. B., & Symann, M. (1998) · Blood · doi:10.1182/blood.v92.5.1471 · Cited by 323
Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes
Rosenberg, S. A., & Lotze, M. T. (1986) · Annual Review of Immunology · doi:10.1146/annurev.iy.04.040186.003341 · Cited by 314
Self-citationTargeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles
Li, J., Ai, Y., Wang, L., Bu, P., Sharkey, C. C., Wu, Q., Wun, B., Roy, S., Shen, X., & King, M. R. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.046 · Cited by 313
Perforin Is a Major Contributor to NK Cell Control of Tumor Metastasis
Smyth, M. J., Thia, K. Y. T., Cretney, E., Kelly, J. M., Snook, M. B., Forbes, C. A., & Scalzo, A. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.11.6658 · Cited by 295
Cell Therapy: Types, Regulation, and Clinical Benefits
El-Kadiry, A. E.-H., Rafei, M., & Shammaa, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756029 · Cited by 256
“LAK cells are PBMCs derived from patients by multiple leukaphereses and incubated with IL-2; they were first demonstrated in 1984 to possess antitumor properties (138).”
MethodThe Role of Tumor Microenvironment in Cancer Immunotherapy
Frankel, T., Lanfranca, M. P., & Zou, W. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_4 · Cited by 173
Metadata
- Authors
- Mazumder, A., & Rosenberg, S. A.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1984-02-01
- Volume
- 159
- Issue
- 2
- Pages
- 495-507
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2153784269
- Cited by
- 369
- References
- 14
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.